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Abstract
Background: Obesity, which is described as excessive or abnormal body fat, increases the risk of diet-related
diseases. In Korea and around the world, the prevalence of obesity has grown annually from 1998 to 2008. This
growth has continued despite various therapeutic efforts. The discovery of new and alternative treatments for
obesity should be considered an important priority. Taeumjowi-tang (TJ001), a traditional Korean medicinal extract
consisting of eight herbs, is a widely used herbal remedy for obesity in Korea. However, the efficacy and safety of
TJ001 have not been fully investigated in a clinical trial. The purpose of this pilot study is to estimate obesity-
related parameters and to assess the efficacy and safety of TJ001.
Methods: Our study is a randomised, double-blind, placebo-controlled, multicentre clinical trial of Taeumjowi-tang
(TJ001). For this study, we will recruit obese Korean patients of both sexes, ages 18 to 65 years, from four university
hospitals. A total of 104 subjects will be recruited. The participants will receive either 7 g of TJ001 or a placebo three times
daily for 12 weeks. The primary end point will be the rate of subjects who lose at least 5% of their baseline body weight.
The secondary end points will be changes in body weight, body mass index, waist circumference, hip circumference,
waist/hip circumference ratio, lipid profiles, body fat composition, blood pressure, fasting glucose concentration, C-
reactive protein and questionnaires related to the quality of life. The outcomes will be measured every 4 weeks. The study
period will be 12 weeks and will include a total of five visits with each subject (at screening and at 0, 4, 8 and 12 weeks).
Conclusions: The results of our study will inform various estimates of TJ001 and will serve as the basis for a larger-
scale trial. This study will assess the efficacy and safety of TJ001 as an alternative herbal remedy for obesity.
Trial registration: Current Controlled Trials ISRCTN87153759
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Background
The World Health Organisation (WHO) defines “obesity”
as abnormal or excessive fat accumulation that may
impair health [1]. Treatment of obesity is important
because this chronic, noncommunicable disease causes
not only a range of health problems, such as
cardiovascular disease, various metabolic syndromes and
certain cancers [1-3], but also social problems. In addi-
tion to the global incidence of obesity, obesity has
become one of the most life-threatening problems in
Korea. The Korea National Health and Nutrition Exami-
nation Survey showed that the overall prevalence of Kor-
ean adult obesity in 2008 was 30.7%, compared with
21.8% in 1998 [4]. The survey defined adults as indivi-
duals who are at least 20 years old, and obesity was
defined as a body mass index (BMI) 25 kg/m
2 according
to the definition of the International Association for the
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WHO [1,5].
Several nonpharmacological attempts to curb the
increase in obesity, including dietary or exercise manage-
ment, have been largely unsuccessful. These failures have
encouraged specialists to develop treatments using phar-
macotherapy [2]. Despite these therapeutic attempts, an
efficacy and safety limit for conventional weight reduction
therapies is apparent [6]. The demand for safe and effective
anti-obesity agents is increasing, and herbal combinations
are meeting those needs [7]. The relative importance and
potential benefits of herbal preparations has extended their
role as possible alternative methods for obesity therapies.
Taeumjowi-tang (TJ001; HANPOONG Pharm & Foods
Co Ltd, Jeonju-si, South Korea) is a traditional Korean
medicine preparation that originated from I Je-ma’s Sasang
constitutional medicine theory [8]. This theory is represen-
tative of the individualised medical approach, which is
widely used to diagnose and treat disease in Korea. The
Sasang typology explains specific disease susceptibility and
drug response differences through distinctive pathology
types. Taeumjowi-tang (TJ001) is a decoction consisting of
eight herbal ingredients and is usually prescribed for Tae-
Eum persons (Greater Yin person, or Tae-Eum-In) to reg-
ulate stomach-related symptoms such as jaundice, anhi-
drosis, stuffiness and the sensation of fullness [8-10].
Owing to the unique pathology of Tae-Eum, these indivi-
duals gain weight more easily than the other three consti-
tutional types (Tae-Yang, So-Eum and So-Yang). The
Sasang typological formulary for Tae-Eum persons con-
tains many therapies related to obesity. Among the various
preparations, TJ001 has become the treatment regimen for
obesity most widely used by Korean medical professionals
[11-15], and its use has been expanded to all types of obe-
sity. Preclinical results have supported the antiobesity and
hypolipidaemic effects of TJ001 [16-19]; however, the
results of clinical studies have been insufficient [20,21].
Although many large, placebo-controlled trials of herbal
combinations and dietary supplements showing antiobesity
effects have been reported [22-27], large-scale trials of
Taeumjowi-tang have not yet been conducted.
This study will be the first reported randomised, double-
blind, placebo-controlled clinical trial of Taeumjowi-tang
(TJ001) in obese adults in Korea. The main purpose of
this study is to assess the efficacy and safety of medicinal
herbal extract of Taeumjowi-tang through a 12-week ran-
d o m i s e dc o n t r o l l e dt r i a l( R C T )t h a tp r o d u c e so b e s i t y -
related estimates.
Methods
Objectives and hypothesis
Objectives
The main objectives of this trial are to (1) evaluate the
efficacy and safety of TJ001 in obese Korean adults, (2)
explore estimates of obesity-related variables, including
the amount of weight reduction, (3) discover the precise
target population, (4) establish an appropriate primary
end point and (5) estimate the proper treatment period.
Hypothesis
We hypothesise that the TJ001 responder rates with a
5% or greater weight reduction will be higher than those
in the placebo group. We also expect that use of TJ001
will be relatively safe.
Study design and period
This study is a 12-week randomised, double-blind, pla-
cebo-controlled, multicentre trial at four tertiary univer-
sity hospitals. Figure 1 shows the schematic flow of the
study.
Study groups
The study will include the following two arms: the
TJ001 group (treatment arm) and the placebo group
(control arm).
Population
The subjects will be obese Koreans of both sexes and
ages 18 to 65 years.
Eligibility criteria
Inclusion and exclusion criteria
The inclusion and exclusion criteria are shown in Table 1.
Subject withdrawal criteria
The subjects who meet the criteria listed in Table 2 will
be discontinued from treatment. The participants who
will be withdrawn after randomisation will be followed
for outcomes.
Interventions
Participating subjects assigned to either the treatment
group or the placebo group will be instructed to take 7 g
of TJ001 or placebo three times daily (a total of 21 g) for
12 weeks (84 days). TJ001 (Taeumjowi-tang granule
extract, HANPOONG Pharm & Foods Co Ltd) is a com-
pound of the powdered extract of several medicinal herbs,
and the placebo will be similar to TJ001 in form, colour
and odour. The components of TJ001 and the placebo are
listed in Table 3.
Lifestyle management
Dietary intake and the type and intensity of exercise will
be recorded by the research coordinator at every visit
but will not be managed strictly.
Dietary instructions
For dietary counselling, the subjects will be counselled to
consume 20 to 25 kcal/kg. In other words, the partici-
pants will be asked to keep their dietary intake approxi-
mately at 1,500 kcal/day for men and 1,200 kcal/day for
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subjects, and they will use a diary to calculate the number
of calories consumed.
Exercise
As the trial will be conducted without lifestyle manage-
ment, the participants will be allowed to maintain their
from four university 
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recruitment  recruitmen nt e
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Figure 1 Flowchart of the Taeumjowi-tang (TJ001) clinical trial.
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a
Criteria
Inclusion criteria
1. Men and women ages 18 to 65 years
2. Individuals who meet one of the following criteria:
2.1. BMI ≥ 30 kg/m
2
2.2. BMI 27 to 30 kg/m
2 with hypertension at a proper treatment- and blood pressure-controlled 95 to 145 mmHg
2.3. BMI 27 to 30 kg/m2 with non-insulin-dependent diabetes mellitus and fasting blood glucose < 7.8 mmol/L (140 mg/dl)
2.4. BMI 27 to 30 kg/m2 with hyperlipidaemia in a proper treatment regimen
2.5. BMI 27 to 30 kg/m2 and ≥ 236 mg/dl total cholesterol or ≥ 150 mg/dl triglycerides at screening
3. Agreed to low-calorie diet during the trial
4. Written informed consent for participation in the trial
5. Written informed consent for the genetic test
Exclusion criteria
1. Endocrine disease such as hypothyroidism or Cushing syndrome
2. Heart disease (heart failure, angina pectoris and/or myocardial infarction)
3. Uncontrolled hypertension (SBP > 145 mmHg or DBP > 95 mmHg)
4. Malignant tumour or lung disease
5. Cholelithiasis
6. Severe renal disability (sCr > 2.0 mg/dl)
7. Severe liver disability (2.5-fold the normal high range value for ALT, AST and ALP)
8. Non-insulin-dependent diabetes mellitus and fasting blood sugar 7.8 mmol/L (140 mg/d or over
9. Narrow-angle glaucoma
10. History or existence of neurological or psychological disease (schizophrenia, epilepsy, alcoholism, drug addiction, anorexia, bulimia and so on)
11. History of stroke or temporary ischaemic cardioplegia
12. History or existence of eating disorder such as anorexia nervosa or bulimia nervosa
13. Use of medication within the past 3 months that could have an effect on weight (appetite suppressant, laxative, oral steroid, thyroid hormone,
amphetamine, cyproheptadine, phenothiazine or medication having an effect on absorption, metabolism and excretion)
14. Use of b-blocker or diuretic as hypertension medication within the past 3 months
15. Use of central nervous system medications or central nervous system stimulating weight reduction medications
16. Forbidden treatments (insulin, hypoglycaemic agent, antidepressant, antiserotonin agent, barbiturate, antipsychotic and concerns related to
medication abuse)
17. Difficult-to-measure anthropometric dimensions due to anatomical changes such as resection surgery
18. History of weight reduction surgery, bariatric surgery and so on
19. Unable to follow instructions during the trial as judged by the investigator
20. Women who are pregnant, lactating, planning a pregnancy or women of child-bearing age who do not agree to proper contraception (birth
control pill, hormone implant, IUD, spermicide, condom, abstinence and so on) (women of child-bearing age indicated to be within 2 years of
menopause who did not receive hysterectomy, bilateral tubal ligation, bilateral oophorectomy, and so on)
21. Use of other investigational products within the past month
22. Weight reduction > 10% within the past 6 months
23. Cessation of smoking within past 3 months or an irregular smoking habit
aALP alkaline phosphatase, ALT alanine aminotransferase, ASTaspartate aminotransferase, BMI body mass index, DBP diastolic blood pressure, IUD intrauterine
device; SBP systolic blood pressure, sCr, serum creatinine
Table 2 Subject withdrawal criteria
Subject withdrawal criteria
1. Protocol violation: detection of eligibility violations, poor compliance (mean compliance < 70% at the last estimation) or noncompliance, use of
any forbidden medication or treatment during the trial that could affect the study results, occurrence of other significant protocol violation during
the trial
2. Occurrence of a serious adverse event
3. Subject has an acute reaction (allergy, shock and so on) to the investigational product
4. Detection of a systemic disease that was not discovered at the screening stage
5. Unable to progress because of worsening of preexisting disease
6. Subject’s withdrawal of consent
7. Subject is uncooperative
8. Investigator’s decision to terminate the process for the sake of the subject’s health
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outs will not be permitted.
Concomitant treatments and forbidden drugs
The subjects will be permitted to use medications only
with the investigator’s permission. The product name, use,
dosage and duration of these medications will be recorded.
The following concomitant treatments will be prohibited:
central nervous system medications; central nervous sys-
tem stimulating weight reduction medications; medica-
tions that could have an effect on weight (insulin,
hypoglycaemic agents, oral steroids, thyroid hormones,
cyproheptadine and phenothiazine); medications that
affect absorption, metabolism or excretion; b-blockers and
diuretics for hypertension treatment; amphetamines; anti-
depressants; antiserotonin agents; barbiturates; antipsycho-
tics; and medicines that increase blood pressure or pulse,
including decongestants that contain phenylpropanola-
mine, ephedrine or pseudoephedrine as well as medicines
for coughs, common colds and allergies.
Sample size calculation
A sample size of 104 subjects was estimated for 80%
power at a significance level of 0.05 and an attrition rate
of 20%. Participants will be selected according to the
eligibility criteria.
No preliminary studies of TJ001 were available to aid
in estimating the percentage of subjects with 5% or
g r e a t e rw e i g h tl o s s[ 2 1 ] .T h e r e f o r e ,w es e tt h er a t ea t
40% for the TJ001 group and 13% for the placebo group
on the basis of a reference paper [28]. The formula for
calculating the sample size when allocating subjects at a
ratio of 1:1 (TJ001:placebo) is as follows:
n =

z1−α

2p

1 − p

+ z1−β

pt

1 − pt

+ pc

1 − pc
2

pt − pc
2
=

1.96
√
2(0.265)(0.735) +0 . 8 4
√
(0.40)(0.735) + (0.13)(0.87)
2
(0.40 − 0.13)2 ≈ 41
pt
The 5% or greater responder rate of the initial weight
in TJ001 group = 40%.
pc
The 5% or greater responder rate of the initial weight
in the placebo group = 13%.
p :

pt + pc

/2 = 26.5% z1−α/2 = 1.96, z1−β =0 . 8 4
Allowing for an attrition rate of 20%, the number of
subjects in each group is 52.
n∗ =
n
(1 − 0.2)
= 51.25 ≈ 52
Therefore, a total of 104 subjects are needed for this
trial.
Randomisation method
The study subjects who satisfy the eligibility criteria will be
randomised using a web-based randomisation program at
an independent centre (Medical Research Collaborating
Center of Seoul National University Hospital http://mrcc.
snuh.org/). This program will be set to allocate partici-
pants equally to each site at a ratio of 1:1. Each of the four
sites will be allocated 26 participants. The TJ001 and pla-
cebo groups will each be allocated 52 participants. The
randomisation program will be designed with a four-
patient block randomisation.
Blinding
Both the investigator and the subject will be blinded
regarding the assignment of the study drugs. The con-
tract research organisation (CRO; Kyung Hee University,
Center for Clinical Research and Genomics) of the
sponsor will label the investigational drugs by the rando-
misation code number. The labelled experimental pro-
ducts will be provided to the trial sites by the CRO.
Recruitment
Participants will be recruited through posted notes on
the bulletin boards at four hospitals: Catholic University
of Korea Seoul St Mary’s Hospital (located in Seoul,
South Korea), Dongguk University Ilsan Oriental Hospi-
tal, Kyungwon Gil Oriental Medical Hospital (Ilsan and
Incheon, South Korea, both satellite cities near Seoul)
and Semyung University Oriental Medicine Hospital
Table 3 Constituents of interventions (TJ001 and
placebo)
a
TJ001 granule
extract
b
Name of herb Raw material code Dose
(g)
Content
(%)
Semen Coicis M040487 3.75 NA
Semen Castaneae M089646 3.75 NA
Semen Raphani M210181 2.5 NA
Schisandrae Fructus M040445 1.25 NA
Liriopis tuber M040139 1.25 NA
Herba Ephedrae M040135 1.25 NA
Radix platycodi M040048 1.25 NA
Acori Tatarinowii
Rhizoma
M051377 1.25 NA
Placebo
Composition Raw material code Dose Content
(%)
Lactose NA NA 87.99%
Starch NA NA 11.73%
Food colouring NA NA 0.28%
aNA not applicable.
bKorea Ministry for Health and Welfare classification 233
(ATC code A16AX).
Park et al. Trials 2012, 13:33
http://www.trialsjournal.com/content/13/1/33
Page 5 of 10(Chungju, a midsized city located in central South
Korea).
Study schedule
The measurements that need to be carried out at each
visit are listed in Table 4.
Measurement tools
Anthropometric measuring for height, weight, waist
circumference and hip circumference
All measurements will be taken by well-trained exami-
ners using standard procedures. Measurements will be
made while participants are dressed in light garments
and with bare feet. Height and weight will be measured
in the standing position to the nearest 0.1 cm and 0.1
kg, respectively. A measuring rod with a movable
headpiece will be mounted on a balance beam scale.
The waist circumference (WC), recorded to the nearest
0.1 cm, will be measured midway between the lower
margin of the last rib and the top of the pelvic bone in
a horizontal plane using plastic tape. The hip circumfer-
ence (HC), recorded to the nearest 0.1 cm, will be mea-
sured at the horizontal level of the widest part of the
hip. BMI is calculated by dividing weight in kilograms
by height in square meters [29]. We will record the sub-
jects’ weight loss in kilograms at every visit and calculate
BMI and the rate of monthly weight loss in both groups
[30].
Questionnaires
Questionnaire for the Sasang Constitution Classifica-
tion II The Questionnaire for the Sasang Constitution
Classification II Sasang Constitution Classification II
Table 4 Study schedule of TJ001 clinical trial (12 weeks)
a
Initial
screening b
Treatment period
Measurement items Visit 1 (-7
days)
Visit 2, week 0
(0 days)
Visit 3, 4 weeks
(28 days)
Visit 4, 8 weeks
(56 days)
Visit 5, 12 weeks
(84 days)
Informed consent Yes
Demographic characteristics
c Yes
Vital signs
d Yes Yes Yes Yes Yes
Medical/drug use history Yes
Smoking/drinking status Yes Yes Yes Yes
Physical examination
e Yes Yes Yes Yes Yes
Laboratory tests
f Yes Yes
Thyroid hormones
g Yes
Lipid test, CRP level
h Yes Yes
Abdominal computed tomography for body fat Yes Yes
Blood sample for genetic test Yes
Electrocardiography Yes
Pregnancy test Yes Yes Yes
Inclusion/exclusion criteria check Yes
Dietary intake measurement
i Yes Yes Yes Yes
Concomitant medication Yes Yes Yes Yes
Adverse event Yes Yes Yes
Questionnaires
j Yes Yes
Questionnaire for Sasang
Constitution Classification Yes
II
Exterior Cold
Disease induced from the Yes Yes Yes Yes
Esophagus affected by
Cold’ questionnaire in Tae-Eum-In persons
Compliance calculation
Yes Yes Yes
aCRP C-reactive protein.
bThe initial screening is performed within 1 week of the start of the study period. The visit windows for each participant are ± 3 days.
cSex, date of birth, age, contact address and telephone number.
dBlood pressure (mmHg), pulse (beats/minute) and body temperature (°C).
eBody weight (kg),
height (cm), waist circumference (cm) and hip circumference (cm).
fBlood tests are performed for haemoglobin, hematocrit, red blood cell count, white blood cell
count, platelet count, total protein, albumin, total bilirubin, alanine transaminase, aspartate transaminase, alkaline g-glutamyltransferase, uric acid, blood urea
nitrogen/creatinine ratio, fasting plasma glucose, creatinine kinase and urine test for colour, specific gravity, pH, protein, glucose, ketone, urobilinogen, bilirubin,
nitrite, red blood cells and white blood cells.
gThyroid-stimulating hormone and free thyroxine are measured at the time of screening.
hTotal cholesterol (mg/dl),
high-density lipoprotein cholesterol (mg/dl), triglyceride (mg/dl) and CRP.
iRecorded in kilocalories using 24-hour dietary recall methods by a dietician or clinical
research coordinator.
jKorean obesity-related quality of life (KOQOL) scale and Korean version of Eating Attitudes Test-26 (KEAT-26).
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according to personal traits based on I Je-ma’sS a s a n g
constitutional medicine theory [31]. We will use this
questionnaire to classify obese Korean adults. Addition-
ally, we will use this questionnaire to evaluate whether
there is an association between each constitutional type
and the effect of TJ001.
Exterior Cold Disease induced from the Oesophagus
affected by Cold questionnaire in Tae-Eum persons
Exterior Cold Disease induced from the Esophagus
affected by Cold questionnaire is used to evaluate symp-
toms that can occur in people of the Tae-Eum constitu-
tional type according to the Sasang constitutional
medicine theory [8]. We will apply this questionnaire to
examine whether there is a relationship between the
tendency toward obesity in Tae-Eum persons and their
response to TJ001.
Compliance All subjects will be asked to return the
remaining investigational products at their next visit,
and the rate of compliance (percentage) will be calcu-
lated on the basis of the returned products.
Compliance(%) = 100 − returned products/expected intake × 100.
Investigational drugs will be distributed in packs of
100 at each visit.
100 = 3times/day × 7days/week × 4weeks/visit + 16extras.
Outcomes
Both primary and secondary end points will be mea-
sured at each visit according to the study schedule
(Table 4).
Primary outcome
The primary outcome is the rate of subjects who have
lost 5% or more of their baseline body weight [28,30,32].
Secondary outcomes
Both within-group and between-group analyses will be
performed for each outcome. The differences in the fol-
lowing variables between the baseline (visit 1) and the
last visit (visit 5) will be calculated.
￿ Body weight (kg)
￿ BMI (kg/m
2)
￿ WC (cm)
￿ HC (cm)
￿ Waist/hip circumference ratio (WHR) change
Lipid profile: total cholesterol, triglyceride, HDL cho-
lesterol, LDL cholesterol levels (mg/dl) (LDL cholesterol
will be estimated using the Friedewald equation [33].)
Body fat composition: visceral fat area (cm
2)a n ds u b -
cutaneous fat area (cm
2) (Body composition will be eval-
uated by abdominal computed tomography.)
￿ Blood pressure (mmHg)
￿ Fasting plasma glucose concentration (mg/dl)
￿ C-reactive protein (mg/L) Questionnaires scores:
Korean Obesity-related Quality of Life (KOQOL) and
Korean version of Eating Attitudes Test-26 (KEAT-26)
Safety outcomes
All variables related to the safety assessment such as
vital signs, general physical examinations, various test
results (hematologic tests, biochemical tests, and urine
tests) and adverse events (AEs) will be documented on
the case report form (CRF) at every visit.
Statistical analysis
Efficacy assessment
T h ep r i m a r yo u t c o m ew i l lb ea n a l y s e du s i n gt h ei n t e n -
tion-to-treat (ITT) method. The secondary outcomes will
be assessed by both the ITT and the per-protocol (PP)
methods. The full analysis set for ITT method will
include all randomised subjects, regardless of their subse-
quent withdrawal after enrolment. The PP analysis will
include patients who have completed the 12-week study
term without any major protocol violations and have a
compliance rate > 70%. Missing values will be replaced
by using the last observation carried forward method.
Continuous variables will be reported as means ± SD,
and categorical variables will be reported as percentages.
The baseline characteristics will be compared by either
Student’s t-test for continuous variables or the c
2 test
(Fisher’s exact test when the expected value is < 5) for
categorical data. Alternatively, McNemar’s test will be
used if the normality assumption is not satisfied for the
continuous variables.
For the within-group analyses, primary and secondary
outcome variables will be evaluated by using a paired t-
test. Alternatively, for nonnormal distribution data, the
Wilcoxon test will be performed. Analysis of covariance
will be applied to analyse differences in each group at
every visit, adjusting for age, baseline weight and BMI as
covariates. Between-group comparisons for each variable
will be performed using Student’s t-test. Statistical signifi-
cance will be defined as P < 0.05. PASW for Windows ver-
sion 18.0 software (SPSS, Inc, Chicago, IL, USA) will be
used for the analyses.
Safety assessment
Safety analyses will be performed for all subjects, who
will be randomised and visited more than once after the
initial screening. Safety-related variables will be analysed
using the ITT method. Safety data will be stratified
according to symptoms.
Adverse event reporting
AEs will be recorded in medical diagnostic terminology.
Detailed symptoms, duration, severity, causal relation-
ships, actions taken, results and other information will be
recorded for each AE. All AEs must be observed and
recorded in the CRF in the AE report section. When an
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the regulatory authorities within 24 hours.
Data quality control, data collection and data
management
Data quality control will be achieved through monitoring
during the trial. After checking the written CRF, well-
trained clinical research associates of the CRO will collect
the data. Data management will be performed by the
CRO, Center for Clinical Research and Genomics, Seoul,
Republic of Korea. All processes will be conducted using
standard operating procedures.
Ethical issues
This study has been approved by the institutional review
boards (IRBs) at each of the four institutions: the IRB of
the Catholic University of Korea Seoul St Mary’s Hospital
(reference KC09MNME0032), the IRB of the Dongguk
University Ilsan Oriental Hospital (ref: SR-09), the IRB of
the Semyung University Oriental Medicine Hospital (refer-
ence 2008-03) and the IRB of the Kyungwon Gil Oriental
Medical Hospital (reference 08-101)). Written informed
c o n s e n tw i l lb eo b t a i n e df r o me a c hi n d i v i d u a lp r i o rt o
enrolment. Research will be performed in compliance with
the Helsinki Declaration and with the Good Clinical Prac-
tice Guidelines.
Discussion
By exploring estimated obesity-related variables, our aim
in this pilot study is to determine the precise target popu-
lation, the primary end point and the intervention period.
Throughout the trial we will evaluate the efficacy and
safety of Taeumjowi-tang. Korea has a dual medical treat-
ment system, and herbal medicine assessments are under
special regulations as described in the WHO legal status
review of traditional medicine. For traditional Korean
medicinal herbs, the Korea Food and Drug Administration
rules specify that they are permitted to be produced
[34,35] if herbal preparations are listed in the 11 classic
traditional Korean and Chinese medicine books [36]. As
these preparations are considered to have historical evi-
dence of efficacy and safety, clinical or toxicological results
can be exempted. Our intervention, Taeumjowi-tang, is
described in one of these classic medical books, the
Donguisusebowon [8]. Despite its long history and wide-
spread usage, few Taeumjowi-tang trials have been pub-
lished [21,27,37]. Therefore, our trial could be considered
a pilot study, and the efficacy and safety of Taeumjowi-
tang should be assessed in a RCT.
We encountered difficulties in deciding several issues.
First, we had difficulty in selecting the target population.
We considered using stratified randomisation, because
weight reduction is affected by sex, age and physical base-
line characteristics such as initial weight and BMI
[3,38,39]. However, these various strata would decrease
the statistical power. We first needed to determine the
general patterns of Korean obesity. To maximise both the
power and the results within given research budgets, we
will include adults over age 18 years and both sexes. We
will carry out stratified analyses with sex as a stratum.
Other covariates, such as age, weight and BMI at the initial
screening visit, will be adjusted.
The second question was what the primary end point
would be. Among various outcomes [40,41], we set a 5%
or greater weight loss responder rate as the primary out-
come because 5% or greater weight loss is considered to
be clinically significant [28,30,32]. As the amount of
weight loss can vary due to initial weight, our study
team concluded that the rate of the subjects who
achieved a weight loss of 5% or more from their baseline
weight would be reasonable compared to the absolute
weight change. Other parameters, such as BMI, weight,
body fat composition and WHR, were set as secondary
outcomes.
Third, we had difficulty in determining the treatment
duration. Though a short-term medication period for
chronic treatment may not be sufficient to observe accu-
rate long-term effects [22,42], we prioritised feasibility.
We decided on a 12-week treatment for the trial after
reflecting on the opinions of the clinicians’ general
experiences and considering both the attrition rate and
the effectiveness of the preparation. Attrition rate will
increase if the treatment duration is prolonged for more
than 3 months. Additionally, according to data reported
in the literature [21,27,32,43,44], the intervention period
of weight reduction ranges from 1 day to 18 months for
complementary therapy RCTs. Among complementary
therapy RCTs, 8-week and 12-week trials are the most
common [23,26,27,44].
Conclusions
We will assess the efficacy and safety of TJ001 in this
trial. On the basis of our research results, we will be
able to determine an adequate target population, a valid
primary end point and an adequate treatment duration
for TJ001. These results will be used to guide a future
large-scale study. In addition, we expect that the results
regarding the relationship between Sasang typology and
obesity will lead us closer to personalised medicine.
Trial status
The trial was first designed in 2009, and the study began
the same year. The study is ongoing, and subject
recruitment has not been completed.
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